S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
S&P 500   4,117.86 (-1.11%)
DOW   33,949.01 (-0.61%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$497.43
-10.25 (-2.02%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$492.97
$504.77
50-Day Range
$399.93
$507.68
52-Week Range
$317.06
$560.92
Volume
539,491 shs
Average Volume
634,540 shs
Market Capitalization
$41.20 billion
P/E Ratio
61.95
Dividend Yield
N/A
Price Target
$514.75

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
4.0% Upside
$514.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.80
Upright™ Environmental Score
News Sentiment
0.53mentions of IDEXX Laboratories in the last 14 days
Based on 37 Articles This Week
Insider Trading
Selling Shares
$7.48 M Sold Last Quarter
Proj. Earnings Growth
14.24%
From $9.48 to $10.83 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

487th out of 1,029 stocks

Diagnostic Substances Industry

8th out of 14 stocks

IDXX stock logo

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in West

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. pixel
Dividend Expert Reveals His Biggest Income Secrets… Free of Charge
Marc Lichtenfeld –Author of the best-selling book Get Rich With Dividends – is giving away his Ultimate Dividend Package… Get His #1 Dividend Stock… The Safest 9% Dividend in the World… Top Three “Extreme Dividend” Stocks, And Much, Much More
IDEXX Stumbles on Q4 and Full-Year Figures
IDEXX Laboratories Sees Higher Earnings, Revenues In FY23 - Update
IDEXX Laboratories Inc Q4 Income Climbs, Beats estimates
IDEXX Laboratories (NASDAQ:IDXX) Updates FY23 Earnings Guidance
IDXX.OQ - | Stock Price & Latest News | Reuters
A Preview Of IDEXX Laboratories's Earnings
IDEXX Laboratories Q4 2022 Earnings Preview
SONVY or IDXX: Which Is the Better Value Stock Right Now?
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings
2/06/2023
Today
2/08/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,350
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$514.75
High Stock Price Forecast
$600.00
Low Stock Price Forecast
$415.00
Forecasted Upside/Downside
+3.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$744.84 million
Pretax Margin
25.54%

Debt

Sales & Book Value

Annual Sales
$3.37 billion
Cash Flow
$6.72 per share
Book Value
$7.35 per share

Miscellaneous

Free Float
81,111,000
Market Cap
$41.20 billion
Optionable
Optionable
Beta
1.17

Social Links


Key Executives

  • Jonathan J. MazelskyJonathan J. Mazelsky
    President, Chief Executive Officer & Director
  • Brian Patrick McKeon
    Chief Financial Officer, Treasurer & Executive VP
  • Ken Grady
    Chief Information Officer & Senior VP
  • Murthy Yerramilli
    Senior Vice President-Research & Development
  • Martin Alexander Smith
    Chief Technology Officer & Executive VP













IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price forecast for 2023?

8 brokerages have issued 1-year price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $600.00. On average, they expect the company's share price to reach $514.75 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2023?

IDEXX Laboratories' stock was trading at $407.96 at the beginning of 2023. Since then, IDXX shares have increased by 23.3% and is now trading at $502.92.
View the best growth stocks for 2023 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Monday, February, 6th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.92 by $0.13. The business earned $828.60 million during the quarter, compared to analysts' expectations of $820.91 million. IDEXX Laboratories had a net margin of 20.17% and a trailing twelve-month return on equity of 124.51%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.89 EPS.
Read the conference call transcript
.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share guidance of $9.27-$9.75 for the period, compared to the consensus earnings per share estimate of $9.50. The company issued revenue guidance of $3.59 billion-$3.69 billion, compared to the consensus revenue estimate of $3.62 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Swiss National Bank (0.41%), LGT Capital Partners LTD. (0.38%), UMB Bank n.a. (0.34%), Robeco Institutional Asset Management B.V. (0.31%), Sumitomo Mitsui Trust Holdings Inc. (0.30%) and Manning & Napier Group LLC (0.21%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $502.92.

How much money does IDEXX Laboratories make?

IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $41.65 billion and generates $3.37 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $8.03 on an earnings per share basis.

How many employees does IDEXX Laboratories have?

The company employs 10,350 workers across the globe.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 2/8/2023 by MarketBeat.com Staff